CompletedNot Applicable

The Role of Interferon-gamma in Immune Responses to Invasive Candidiasis

United States87 participantsStarted 2022-02-10

Plain-language summary

The purpose of the study is to investigate the role of the human immune response to candidemia/invasive candidiasis as it relates to the cytokine interferon-gamma.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Willing and able to provide written informed consent. If the subject is unable to consent for himself/herself, a legally authorized representative must provide informed consent on his/her behalf.
✓. Males or females ≥18 years of age
✓. Patients having one or more systemic signs attributable to candidemia or invasive candidiasis (fever, hypothermia, hypotension, tachycardia, tachypnea, local signs of inflammation).
✓. Isolation of Candida from blood, intra-abdominal abscess/peritoneal fluid or pleural fluid.

Exclusion criteria

✕. Severe neutropenia (absolute neutrophil count \<500 cells/microL)
✕. Profound lymphopenia (\<300 cells/microL)
✕. The Principal Investigator (PI) is of the opinion the subject should not participate in the study.
✕. Females who are pregnant.

What they're measuring

All-cause mortality

Timeframe: 30 days

Trial details

NCT IDNCT05235711

SponsorMayo Clinic

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-08-31

View on ClinicalTrials.gov More Fungal Infection trials